Arkolith/Insider Trading/TNGX/Form 4

Weber Barbara

Chief Executive Officer, DirectorTango Therapeutics, Inc. (TNGX) · full profile →Form 4 · filed Feb 5, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2025Grant(A)106K—$01.6M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 3, 2025Grant(A)635K—$0635K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-014810) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML